ABG Innovation Capital Partners III GP Ltd - Q3 2021 holdings

$2.41 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 6 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 42.9% .

 Value Shares↓ Weighting
NewAADI BIOSCIENCES INC$783,00026,666
+100.0%
32.53%
GNCA  GENOCEA BIOSCIENCES INC$720,000
-18.0%
375,0000.0%29.91%
+917.8%
SYBX  SYNLOGIC INC$628,000
-21.6%
205,9060.0%26.09%
+872.8%
LUNG  PULMONX CORP$163,000
-18.1%
4,5210.0%6.77%
+916.8%
IDRA  IDERA PHARMACEUTICALS INC$58,000
-14.7%
56,2500.0%2.41%
+957.0%
 NABRIVA THERAPEUTICS PLC$55,000
-11.3%
45,8490.0%2.28%
+998.6%
ARPO ExitAERPIO PHARMACEUTICALS INC$0-400,000
-100.0%
-2.26%
AVIR ExitATEA PHARMACEUTICALS INC$0-1,265,631
-100.0%
-91.01%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Fan Yu #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-11-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SYNLOGIC INC12Q3 202333.8%
AADI BIOSCIENCES INC9Q3 202337.2%
IDERA PHARMACEUTICALS INC9Q4 20222.4%
GENOCEA BIOSCIENCES INC8Q3 202232.1%
NABRIVA THERAPEUTICS PLC7Q2 20222.3%
CASTLE BIOSCIENCES INC6Q3 202377.2%
PULMONX CORP5Q4 202133.9%
AERPIO PHARMACEUTICALS INC3Q2 20212.3%
ATEA PHARMACEUTICALS INC2Q2 202191.0%
ATEA PHARMACEUTICALS INC1Q1 202180.1%

View ABG Innovation Capital Partners III GP Ltd's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View ABG Innovation Capital Partners III GP Ltd's complete filings history.

Compare quarters

Export ABG Innovation Capital Partners III GP Ltd's holdings